The intended audience for this activity is comprehensive ophthalmologists and optometrists involved in the management of patients with Demodex blepharitis. In support of improving patient care ...

We can tell a lot about our health from looking at our eyes. If you spot any these warnings signs from your eyes, you shouldn ...

Experts share their advice on why we need to change those mascaras and make-up products that we have kept for years.

Frantz EyeCare’s highly-trained specialists strive to provide the most advanced treatment for healthy eyes in all phases of ...

Shares of LianBio (NASDAQ:LIAN – Get Free Report) traded down 2.1% during mid-day trading on Friday . The company traded as low as $0.20 and last traded at $0.20. 14,001 shares were traded during ...

XDEMVY (lotilaner ophthalmic solution, 0.25%) is FDA approved in the United States for the treatment of Demodex blepharitis. Tarsus is also developing TP-04 for the potential treatment of Ocular ...

Tarsus Pharmaceuticals sees growth with Xdemvy's $180M sales in 2024. Read this article to know what makes TARS stock a BUY for growth investors.

Its product candidate, TP-03, is a novel therapeutic in Phase 2b/3 that is being developed for the treatment of blepharitis caused by the infestation of Demodex mites, which is referred to as ...

Detailed price information for Tarsus Pharmaceuticals Inc (TARS-Q) from The Globe and Mail including charting and trades.

Bradley Walsh has been battling blepharitis, an eye condition that can cause itchy and swollen eyelids. During an appearance on This Morning, he opened up about the harsh comments he'd faced ...